The objective of this study is to examine the effect of hydrodynamic delivery of plasmid containing Il-15 gene on high fat dietinduced obesity and obesity-associated metabolic disorders. We demonstrate that Il-15 gene transfer results in multiple beneficial effects, including blockade of weight gain, alleviation of fatty liver and improvement in glucose homeostasis in mice. These effects are accompanied by suppressed expression of genes involved in lipogenesis and gluconeogenesis including Scd-1, Fas, Pdk4, Pepck and G6p, and enhanced expression of genes responsible for lipolysis and glucose metabolism such as Cpt1-α, Cpt1-β, Acadm, Acadl and Glut-4. Collectively, our results suggest that Il-15 gene transfer is an effective approach in preventing diet-induced obesity and obesity-associated complications.
INTRODUCTION
Obesity is a major risk factor in the development of several diseases including diabetes, cardiovascular diseases, metabolic disorders and cancer. 1, 2 With an increasing prevalence of obesity, physical exercise is often recommended as a means of effectively preventing weight gain or losing weight for people who are obese. 3 At the molecular level, muscle contraction is associated with release of cytokines such as interleukin 6 (IL-6), IL-8 and IL-15 that work to send signals to the liver and adipose tissue for glycolysis and lipolysis, generating glucose to support muscle activities. While the detailed mechanism on how these cytokines work remains illusive and controversial, exercise-induced IL-6 is believed to suppress inflammation by increasing cytokine inhibitors such as IL-1 receptor antagonist and soluble tumor necrosis factor-α receptors, and triggering the release of the major anti-inflammatory cytokine IL-10. 4 Exercise-induced IL-8, on the other hand, serves as a potent angiogenic factor that signals the need for building more blood vessels in muscle. 5 Different from IL-6 and IL-8, muscle-released IL-15 works by interacting with transcription factor such as peroxisome proliferator activated receptor to enhance lipolysis and reduce the adipose tissue size. 6 In the past, IL-15 has been considered an anti-obesity cytokine although its therapeutic potential has not been demonstrated. 7 Evidence supporting the role of IL-15 in lipid metabolism and obesity is accumulating. Yang et al. 8 have shown that IL-15 level is markedly lower in obese than control rats. Studies of Il-15 knockout mice showed a higher fat mass than wild-type animals. 9 Similarly, Il-15 transgenic mice exhibit lower body weight and resistance to high fat diet (HFD)-induced obesity. 6 In addition, Il-15 transgenic mice ran twice as long as littermate control in a run-to-exhaustion trial and preferentially used fat for energy metabolism. 10 In this study, we assessed the activity of IL-15 in blocking HFD-induced obesity, insulin resistance and fatty liver development.
Using a well-established gene transfer technique to overexpress Il-15 gene in mice fed a HFD, we demonstrate that Il-15 gene transfer results in sustained Il-15 expression and blocked HFDinduced obesity and obesity-associated metabolic diseases. Our results suggest that Il-15 gene transfer is an effective approach in blocking HFD-induced obesity, and development of insulin resistance and liver steatosis.
RESULTS

Hydrodynamic gene transfer resulted in elevated mRNA levels of
Il-15 in the liver and increased serum concentrations of IL-15 protein in HFD feeding mice Two hydrodynamic tail vein injections of pLIVE-mIL-15 or pLIVE-SEAP plasmids were performed on days 1 and 31, respectively, on C57BL/6 mice on a HFD. Relative mRNA levels at the end of the 9-week feeding period were examined and showed~54-fold higher in the liver, but not in the muscle (Figure 1a ), confirming the liver specificity of the hydrodynamic procedure of gene delivery. 11, 12 The IL-15 protein level was~420 pg ml − 1 in the blood (Figure 1b ). No significant increase in serum concentrations of liver-specific enzymes either alanine aminotransferase (ALT) ( Figure 1c ) or aspartate aminotransferase (AST) ( Figure 1d ) was observed, indicating absence of liver damage.
Il-15 gene transfer blocked HFD-induced obesity in mice
The effect of Il-15 gene delivery on diet-induced obesity was examined. Mice that received secreted embryonic alkaline phosphatase (SEAP) gene transfer showed a significant increase in body weight as early as 3 weeks when fed a HFD, compared with animals fed a HFD and injected with the Il-15 gene (Figure 2a ). At the end of the 9-week HFD feeding, the SEAP gene injected control mice showed an average body weight of 39.8 ± 2.0 g, about 10 g higher than mice injected with Il-15 gene (29.0 ± 2.4 g), almost identical to mice fed a regular chow (29.4 ± 1.8 g). The size difference among the three groups of mice is visually differentiable (Figure 2b ). Body composition analysis using the EchoMRI-100 system (EchoMRI, Houston, TX, USA) showed that Il-15 gene transfer, compared with chow-fed regular mice, blocked the fat mass gain without changing lean mass (Figures 2c and d). No significant difference was seen in average energy intake among the animals (Figure 2e ). Together, these results demonstrate that hydrodynamic delivery of Il-15 gene completely blocked HFD-induced obesity.
Il-15 gene transfer suppressed hypertrophy in adipocytes
To explore the impact of Il-15 gene transfer on morphological change in adipocytes, we collected adipose tissue from the control and IL-15-treated mice. The average size of adipocytes ( Figure 3a ) and weight of fat pads (Figure 3b ) were measured and showed a significant difference in epididymal, inguinal, and perirenal white adipose tissues, and brown adipose tissue (BAT) between HFD-fed control and IL-15-treated mice. Compared to control mice injected with pLIVE-SEAP plasmid, hematoxylin and eosin (H&E) staining of white adipose tissue shows Il-15 gene transfer significantly suppressed HFD-induced enlargement of adipocytes in epididymal, perirenal, and inguinal white adipose tissues, and fat accumulation, judging by size and number of vacuoles in BAT ( Figure 3c ). The average diameter of adipocytes in HFD-fed control mice is 89.8 ± 9.9 μm, compared to 52.5 ± 8.6 μm in IL-15-treated mice and 44.7 ± 6.3 μm in mice fed a regular chow ( Figure 3d ). No significant difference was observed between animals fed a regular chow and HFD with Il-15 gene transfer.
Il-15 gene transfer prevented HFD-induced fatty liver Excessive fat deposition in the liver is one of the major physiological changes associated with obesity. Therefore, we examined the effect of Il-15 gene delivery on lipid accumulation in the liver. Mice transferred with the Il-15 gene showed lower liver weights compared with those of HFD-fed control ( Figure 4a ). Histological images showed more vacuoles in liver sections of HFD-fed control mice ( Figure 4b ). Oil-red O staining confirmed a significant presence of lipid droplets ( Figure 4b ) in HFD-fed control mouse liver and Il-15 gene transfer blocked HFD-induced lipid accumulation in the liver. Biochemical quantitation showed lower levels of triglyceride (TG) in the liver of IL-15-treated mice ( Figure 4c ). Again, there is no statistical difference between IL-15-treated mice and those fed a regular chow.
Il-15 gene transfer modulates transcription of genes involved in lipid metabolism
To investigate how Il-15 gene transfer reduced excessive lipid accumulation in HFD-fed animals, we measured mRNA levels of genes in the liver and the muscle involved in de novo lipogenesis and lipolysis. We first compared mRNA levels of genes with known functions for lipogenesis including Scd-1, Fas and Acc-1. HFD feeding increased the expression of Scd-1 and Fas in muscle bỹ 8.6-and~3.1-folds, respectively ( Figure 5a ). Il-15 gene transfer significantly reduced mRNA levels of the same set of genes in the muscle by~58.6% and~51.1%, as well as~63.7% and~49.4% in the liver (Figures 5a and b ). mRNA levels of Acc-1 did not change in the muscle or liver. Next, we evaluated mRNA levels of critical genes for fatty acid β oxidation in both muscle and liver. HFD-fed mice received Il-15 gene transfer showed a slight, but significant Il-15 gene transfer protected mice from HFD-induced hyperinsulinemia and hyperglycemia Obesity is a known risk factor in developing insulin resistance, one characteristic of type-2 diabetes. We then conducted an intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance test (ITT) to investigate whether mice transferred with the Il-15 gene show an improvement in glucose metabolism. Il-15 gene transfer decreased fasting glucose (~148 mg dl − 1 ) levels compared with HFD-fed control mice (~222 mg dl − 1 ) ( Figure 6a ). Mice fed a HFD for 8 weeks become glucose intolerant judging by IPGTT ( Figure 6b ). The calculated area under the curve (AUC) of IPGTT showed that HFDfed mice transferred with the Il-15 gene exhibited normal glucose sensitivity comparable to that of control animals fed a regular diet. Blood insulin levels in mice fed a chow diet, HFD with injection of control plasmids, and those fed a HFD with Il-15 gene transfer werẽ 2.2,~6.2 and~1.6 ng ml − 1 , respectively (Figure 6d ). Similarly, results from ITT showed HFD-fed control mice developed insulin resistance ( Figure 6e 
Il-15 gene transfer affects the expression of critical genes involved in glucose metabolism
To investigate how Il-15 gene transfer maintained glucose homeostasis, we measured the mRNA levels of genes involved in glucose metabolism in the liver and the muscle. Expression of Pdk4, a key gene involved in repressing glucose oxidation, was increased in HFD-fed control mice in the liver, while Il-15 gene transfer significantly reduced its mRNA levels by~33.5% (Figure 7a ). Expressions of genes involved in gluconeogenesis, such as Pepck and G6p, were decreased in IL-15-treated mice bỹ 29.8% and 41.8%, respectively ( Figure 7a ). Expression of Glut-4, a critical gene involved in glucose transportation, was reduced in HFD fed control mice in muscle. However, mice transferred with the Il-15 gene slightly, but significantly enhance the mRNA levels of Glut-4 by~1.8 folds ( Figure 7b ).
DISCUSSION
Exercise-associated factors, including IL-15, have remarkable roles in glucose and lipid metabolism and energy expenditure. 7, 13 Our group has previously shown that hydrodynamic injection of the FGF-21 gene alleviated obesity and fatty liver in mice fed a HFD. 14 In the present work, we demonstrate that Il-15 gene transfer generates a higher serum concentration of IL-15 during the 9-week experimental time period (Figure 1 ), resulting in a blockade of HFD-induced obesity and alleviation of obesity-related hepatic fat accumulation and glucose intolerance (Figures 2, 3, 4 and 6) . Mechanistically, these beneficial effects were accompanied with suppressed expression of genes involved in de novo lipogenesis and gluconeogenesis, as well as increased expression of genes involved in lipolysis and glucose transport ( Figures 5 and 7) .
Accumulating evidence suggests that IL-15 has a direct effect on adipose tissue. A previous study by Carbo et al. 15 demonstrates that 7 days administering IL-15 to adult rats led to a 33% decrease in white adipose tissue, suggesting an anti-adipogenic role of the IL-15. These observations were confirmed using different types of mammalian adipogenic cell lines, including human-derived cells. 9, 16, 17 Moreover, IL-15 administration was able to inhibit pre-adipocyte differentiation and lipid deposition. 16, [18] [19] [20] In agreement with previous reports, we observed that Il-15 gene transfer blocked HFD-induced weight (Figure 2a ) and fat mass gain (Figure 2c ). Meanwhile, results from a histological analysis revealed a smaller diameter of adipocytes in the white adipose tissue and less lipid accumulation in the liver (Figures 3c and 4b) .
These results suggest that the function of IL-15 involves a blockade of adipogenesis. Previous studies identified IL-15 as a key regulator for enhancing lipid oxidation and suppressing de novo lipogenesis. Using a primary pig model, Ajuwon et al. 17 have shown that IL-15 directly targeted adipocytes through lipolysis and lipogenesis. Similarly, Lopez-Soriano et al. 21 demonstrated that daily injections of IL-15 reduced activity of lipogenic enzyme, such as ACC and FAS, leading to decreased lipogenic rate and carcass fat. Consistent with these findings, we observed Il-15 gene transfer repressed expression of Scd-1 and Fas genes in the liver and the muscle, which are involved in de novo lipogenesis (Figures 5a and b) . However, we did not observe a significant change in Acc-1 gene expression. Moreover, Il-15 gene transfer in mice fed a HFD increased transcription of several key genes for lipid oxidation, including Cpt1-α, Cpt1-β, Acadm and Acadl (Figures 5c and d) , leading to a corresponding alleviation of adipocyte deposition and fatty liver (Figures 3 and 4) .
IL-15 also has important roles in maintaining glucose homeostasis by facilitating glucose uptake in skeletal muscle. Previous studies by Busquets et al. 22 demonstrate that IL-15 stimulates glucose uptake in skeletal muscle by increasing Glut-4 expression both in vivo and in vitro. Barra et al. 23 provided compelling evidence showing IL-15 treatment is able to improve glucose homeostasis and insulin sensitivity in diet-induced obese mice. Consistent with these previous reports, our data clearly show that Il-15 gene transfer markedly reduces insulin resistance and improved glucose tolerance in mice fed an HFD ( Figure 6 ). In addition, expression of the genes involved in glucose metabolism including Pdk4, Pepck and G6p was decreased in the liver of mice with overexpression of Il-15 (Figure 7a ). Glut-4, a critical gene involved in glucose transportation was upregulated in muscle ( Figure 7b ).
In summary, in this study, we demonstrate that hydrodynamic delivery of Il-15 gene brought a variety of beneficial effects in dietinduced obesity and its complications, including suppression of adiposity, alleviation of fatty liver and improvement of insulin resistance. Our findings indicate that Il-15 gene transfer could be an effective approach in preventing HFD-induced obesity and obesity-associated fatty liver and insulin resistance.
MATERIALS AND METHODS
Plasmid vectors
The pLIVE plasmid vector was purchased from Mirus Bio (Madison, WI, USA), and either the mouse IL-15 (mIl-15) or SEAP gene was cloned into the pLIVE vector. Il-15 gene fragment was inserted into multi-cloning sites of the pLIVE vector created by restriction digestion of Sac Ι and Xho Ι. Plasmid constructs were confirmed by DNA sequencing (University of Georgia Genomics Facility). The plasmids were isolated using the method of cesium chloride density gradient centrifugation (spun twice) and kept in saline at − 80°C until use. Lack of endotoxin in plasmid preparation was confirmed by ELISA using the ELISA kit from eBioscience, Inc. (San Diego, CA, USA). Optical density determination (260 and 280 nm) and 1% agarose gel electrophoresis were conducted to verify the purity of the plasmid preparations.
Animals and animal procedure
Male C57BL/6 mice (9 weeks old, 24-26 g) were purchased from Charles River Laboratories (Wilmington, MA, USA) and housed under standard conditions with a 12 -to 12-h light-dark cycle. The HFD (60% kcal from fats, 20% from carbohydrates and 20% from proteins) was purchased from Bio-Serv (Frenchtown, NJ, USA; #F3282). Mice were fed continuously for 9 weeks and body weight, body composition and food intake were measured weekly. Blood and various tissue samples were collected after killing the mice for biochemical and histological examinations. All animal experiments were approved by the Institutional Animal Care and Use Committee at the University of Georgia, Athens, Georgia (protocol number, A2011 07-Y2-A3).
Hydrodynamic gene delivery of either pLIVE-SEAP plasmid (control) or pLIVE-IL-15 plasmids was performed on days 1 and 31 when animals were fed a selected diet. Briefly, 9% body weight of saline solution containing 10 μg of plasmid DNA was injected into mouse tail vein within 5-8 s. 12 Mouse IL-15 levels in serum were quantified using an IL-15 Duoset ELISA kit (R&D Systems, Minneapolis, MN, USA).
Gene expression analysis by real-time PCR
Total RNA was isolated from the mouse liver and muscle using TRIzol reagents from Invitrogen (Carlsbad, CA, USA). Reverse transcription PCR (RT-PCR) was conducted using commercial kits from OriGene (Rockville, MD, USA). Real-time PCR (qPCR) was performed using SYBR Green as the detection reagent on the ABI StepOne Plus Real-Time PCR system. 24 GAPDH mRNA was used as an internal control, and all primers ( Table 1) were ordered from Sigma (St Louis, MO, USA). A melting curve analysis of all quantitative PCR products was performed and showed a single DNA duplex.
Determination of plasma concentrations of ALT and AST
Blood samples were collected from heart cavities immediately after euthanizing mice. Serum was isolated by centrifugation at 5000 r.p.m. for 5 min. ALT and AST concentrations were determined using commercial kits from Thermo Scientific (Middletown, VA, USA), following the manufacturer's instruction.
Determination of liver TG level
The procedure was performed according to the Folch method. 25 Briefly, liver samples (~150 mg) were homogenized in a mixture of chloroform and methanol (2:1, volume ratio). Tissue homogenates were incubated at 4°C overnight and centrifuged at 12 000 r.p.m. for 20 min. The supernatants were air dried and re-dissolved in 3% Triton-isopropanol. The amounts of liver TG were determined using a commercial kit from Thermo-Scientific.
Evaluation of glucose homeostasis
IPGTT and ITT were carried out 1 week before the end of the experiments. For IPGTT, mice were fasted for 6 h and glucose in 0.9% saline was injected (i.p.) at 2 g kg − 1 , with the time point was set as 0 min. Blood glucose levels were measured at 0, 30, 60, and 120 min using glucose test strips and glucose meters. The same group of animals was allowed to rest for 2 days after IPGTT. For ITT, animals were fasted for 4 h and insulin (Humulin) from Eli Lilly (Indianapolis, IN, USA) was injected (i.p.) at a dose of 0.75 U kg − 1 , and blood glucose was measured in a time course identical to IPGTT. Insulin levels in the blood were measured using a commercial ELISA kit (Mercodia Developing Diagnostics, Winston Salem, NC, USA). Insulin resistance (HOMA-IR) was calculated using the following formula: HOMA-IR = (fasting insulin (ng ml − 1 ) × fasting plasma glucose (mg dl − 1 )/405).
H&E staining
Freshly collected tissues were fixed in 10% neutral buffered formalin. After gradient dehydration and embedding, tissue were sectioned at a thickness of 5-7 μm and dried at 37°C for 1 h. Standard H&E staining was performed following the manufacturer's instruction of a commercial kit from BBC Biochemical (Atlanta, GA, USA). Microscopic examination was performed and diameters of adipocytes in white adipose tissue were measured using the NIS-Elements imaging platform from Nikon Instruments Inc. (Melville, NY, USA).
Oil-red O staining
Fresh liver samples were immediately collected from killed animals and frozen in liquid nitrogen. Frozen sections were made at 8 μm using a Cryostat and fixed in 10% neutral buffered formalin for 30 min. The tissue slides were washed with phosphate-buffered saline and rinsed with 60% isopropanol for 5 min before being stained with freshly prepared Oil-red O working solution (Electron Microscopy Sciences, Hatfield, PA, USA) for 30 min. Tissue sections were rinsed by isopropanol (60%) for 5 min and stained with hemotoxylin for 1 min. Slides were examined using an optical microscope from Nikon Instrument Inc. (Melville, NY, USA), and selected structures were photographed.
